Table 3 Analyses of prognostic factors for survival

Sex (female VS male)

0.639 (0.222–1.835)

1.284 (0.534–3.086)

Age (per 1 point increase)

1.027 (0.993–1.063)

1.001 (0.972–1.030)

Age group (≥ 65 VS < 65)

2.467 (1.153–5.279)

2.545 (1.113–5.823)

1.507 (0.734–3.094)

ECOG PS (per 1 point increase)

1.363 (0.664–2.802)

1.679 (0.891–3.164)

BCLC stage (C VS B)

2.185 (0.829–5.756)

1.922 (0.843–4.379)

Tumor size (per 1 point increase)

1.010 (1.003–1.017)

1.010 (1.003–1.017)

1.006 (1.000–1.012)

-

Tumor size (≥ 10 cm VS < 10 cm)

2.200 (1.050–4.613)

-

1.523 (0.803–2.890)

Tumor distribution (multiple VS single)

2.190 (0.663–7.233)

1.890 (0.668–5.344)

Child–Pugh class (B VS A)

1.927 (0.878–4.232)

1.913 (0.965–3.791)

-

Extrahepatic metastases (Yes VS No)

1.638 (0.796–3.367)

1.412 (0.757–2.636)

Macrovascular invasion (Yes VS No)

2.533 (1.151–5.574)

-

2.332 (1.174–4.632)

2.193 (1.083–4.443)

Liver Cirrhosis (Yes VS No)

0.444 (0.126–1.563)

0.634 (0.218–1.843)

Hepatitis B (Yes VS No)

0.562 (0.210–1.504)

0.965 (0.372–2.501)

Co-treatment time (late combination VS early combination)

0.200 (0.077–0.522)

0.175 (0.060–0.509)

0.310 (0.144–0.665)

0.422 (0.184–0.967)

AFP (≥ 200 VS < 200)

1.946 (0.892–4.244)

-

1.846 (0.937–3.636)

-

RBC

0.956 (0.599–1.526)

0.880 (0.590–1.312)

WBC

0.941 (0.769–1.153)

0.892 (0.740–1.075)

Platelet

1.004 (1.000–1.007)

-

1.002 (0.999–1.006)

Hb

0.993 (0.977–1.011)

0.990 (0.976–1.005)

Neutrophils

1.018 (0.829–1.249)

0.967 (0.803–1.166)

Lymphocyte

0.377 (0.166–0.854)

-

0.410 (0.200–0.842)

-

NLR

1.074 (0.916–1.259)

1.078 (0.938–1.240)

ALT

1.004 (0.995–1.014)

1.003 (0.996–1.010)

AST

1.004 (0.998–1.009)

1.003 (0.999–1.008)

TBIL

1.006 (0.973–1.040)

1.002 (0.971–1.034)

ALP

1.005 (1.002–1.008)

-

1.004 (1.002–1.007)

1.004 (1.001–1.007)

TBA

0.994 (0.982–1.007)

1.000 (0.994–1.006)

ALB

0.949 (0.884–1.018)

0.948 (0.892–1.008)

-